Researchers in the Folkman lab were the first to determine that certain angiogenesis inhibitors could block the female reproductive cycle at several key stages, suggesting an entirely new role for these compounds. Currently, they are studying various antiangiogenic agents as potential forms of contraception. If this research is successful, it would offer a nonhormonal method of birth control and could become an inexpensive option for developing countries concerned about overpopulation.

Maria Rupnick, Christian Becker, and others in the Folkman Lab are looking at whether angiogenesis inhibitors may have a role in treating endometriosis, which is characterized by the migration of tissue from the lining of the uterus to the ovaries, urethra and other pelvic structures. The migrant tissue waxes and wanes just as the endometrium does during the menstrual cycle. As it grows, it can interfere with ovarian function and become a source of pain. Angiogenesis inhibitors may be able to "starve" the unwanted tissue by robbing it of its rich blood supply.